Added to YB: 2024-07-05
Pitch date: 2024-07-04
MEDXF [bullish]
Medexus Pharmaceuticals Inc.
+23.84%
current return
Author Info
Stock Spin-Off Investing is a former equity and PE researcher who shares spin-off related content. Visit the website.
Company Info
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases.
Market Cap
CAD 62.3M
Pitch Price
CAD 1.51
Price Target
10.00 (+421%)
Dividend
N/A
EV/EBITDA
4.50
P/E
67.58
EV/Sales
0.71
Sector
Pharmaceuticals
Category
special_situation
Stock Spin-off Investing: Buy Medexus Pharma
MEDXF: 2x FCF, 5.2x EBITDA, 2.2x net debt/EBITDA. FDA decision on Treosulfan by Oct 30; approval could double rev, triple EBITDA/FCF in 3yrs. Insiders own 10%+, buying more. $10 PT if approved (5.3x EV/EBITDA on $60M EBITDA). Limited downside due to cheap valuation, stable biz, Q1 2025 terbinafine catalyst ($20-30M/yr opportunity).
Read full article (1 min)